Fluorofenidone attenuates pulmonary inflammation and fibrosis via inhibiting the activation of NALP3 inflammasome and IL-1β/IL-1R1/MyD88/NF-κB pathway

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 11, 2016, Pages 2064-2077

  Song, Cheng ^a,b   He, Lujuan ^a   Zhang, Jin ^a   Ma, Hong ^a   Yuan, Xiangning ^a   Hu, Gaoyun ^c   Tao, Lijian ^a   Zhang, Jian ^d   Meng, Jie ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

fluorofenidone; IL 1 IL 1R1 MyD88 NF B pathway; NALP3 inflammasome; pulmonary fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; CRYOPYRIN; FIBRONECTIN; FLUOROFENIDONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; MYELOPEROXIDASE; REACTIVE OXYGEN METABOLITE; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; 5-METHYL-1-(3-FLUOROPHENYL)-2-(1H)-PYRIDONE; ACTA2 PROTEIN, MOUSE; ACTIN; BLEOMYCIN; CCL2 PROTEIN, MOUSE; INFLAMMASOME; INTERLEUKIN RECEPTOR; NLRP3 PROTEIN, HUMAN; PEROXIDASE; PYRIDONE DERIVATIVE; URIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LUNG FIBROSIS; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COMPLICATION; DOWN REGULATION; DRUG EFFECTS; LUNG; METABOLISM; PATHOLOGY; PULMONARY FIBROSIS; SIGNAL TRANSDUCTION;

ACTINS; ANIMALS; BLEOMYCIN; CASPASE 1; CHEMOKINE CCL2; COLLAGEN TYPE I; DOWN-REGULATION; FIBRONECTINS; HUMANS; INFLAMMASOMES; INTERLEUKIN-1BETA; INTERLEUKIN-6; LUNG; MALE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PEROXIDASE; PNEUMONIA; PULMONARY FIBROSIS; PYRIDONES; REACTIVE OXYGEN SPECIES; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION; URIC ACID;

EID: 84992461067     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12898     Document Type: Article

References (34)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183: 788–824.
2. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001; 134: 136–51.
3. Keane MP, Strieter RM, Belperio JA. Mechanisms and mediators of pulmonary fibrosis. Crit Rev Immunol. 2005; 25: 429–63.
4. Beeh KM, Beier J, Kornmann O, et al. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med. 2003; 97: 634–9.
5. Manoury B, Nenan S, Leclerc O, et al. The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respir Res. 2005; 6: 11.
6. Madtes DK, Elston AL, Kaback LA, et al. Selective induction of tissue inhibitor of metalloproteinase-1 in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2001; 24: 599–607.
7. Postlethwaite AE, Raghow R, Stricklin GP, et al. Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta. J Cell Biol. 1988; 106: 311–8.
8. Gasse P, Mary C, Guenon I, et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest. 2007; 117: 3786–99.
9. Yu HB, Finlay BB. The caspase-1 inflammasome: a pilot of innate immune responses. Cell Host Microbe. 2008; 4: 198–208.
10. Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci. 1998; 856: 1–11.
11. Gasse P, Riteau N, Charron S, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med. 2009; 179: 903–13.
12. Riteau N, Gasse P, Fauconnier L, et al. Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med. 2010; 182: 774–83.
13. Kirsten D. Pulmonary sarcoidosis: current diagnosis and treatment. Dtsch Med Wochenschr. 2013; 138: 537–41.
14. Kim SK, Choe JY, Park KY. Rebamipide suppresses monosodium urate crystal-induced interleukin-1beta production through regulation of oxidative stress and caspase-1 in THP-1 cells. Inflammation. 2016; 39: 473–82.
15. Haddad JJ. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal. 2002; 14: 879–97.
16. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol. 2003; 54: 469–87.
17. Lou Q, Meng X, Lao Z, et al. Design, synthesis and antifibrotic activities of carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1H) pyridones. Molecules. 2012; 17: 884–96.
18. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 35: 821–9.
19. Peng Y, Yang H, Wang N, et al. Fluorofenidone attenuates hepatic fibrosis by suppressing the proliferation and activation of hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2014; 306: G253–63.
20. Peng Y, Yang H, Zhu T, et al. The antihepatic fibrotic effects of fluorofenidone via MAPK signalling pathways. Eur J Clin Invest. 2013; 43: 358–68.
21. Meng J, Zou Y, Hu C, et al. Fluorofenidone attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice via restoring caveolin 1 expression and inhibiting mitogen-activated protein kinase signaling pathway. Shock. 2012; 38: 567–73.
22. Szapiel SV, Elson NA, Fulmer JD, et al. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis. 1979; 120: 893–9.
23. Martinon F, Gaide O, Petrilli V, et al. NALP inflammasomes: a central role in innate immunity. Semin Immunopathol. 2007; 29: 213–29.
24. Martinon F. Signaling by ROS drives inflammasome activation. Eur J Immunol. 2010; 40: 616–9.
25. Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010; 10: 210–5.
26. Behr J, Thannickal VJ. Update in diffuse parenchymal lung disease 2008. Am J Respir Crit Care Med. 2009; 179: 439–44.
27. Azuma A. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2012; 6: 107–14.
28. Kolb M, Margetts PJ, Anthony DC, et al. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest. 2001; 107: 1529–36.
29. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440: 237–41.
30. Chen CJ, Shi Y, Hearn A, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest. 2006; 116: 2262–71.
31. Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010; 11: 136–40.
32. Zhou R, Yazdi AS, Menu P, et al. A role for mito-chondria in NLRP3 inflammasome activation. Nature. 2011; 469: 221–5.
33. Bartfai T, Behrens MM, Gaidarova S, et al. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc Natl Acad Sci USA. 2003; 100: 7971–6.
34. Boraschi D, Tagliabue A. The interleukin-1 receptor family. Vitam Horm. 2006; 74: 229–54.